JDR Jourdan

RNS Number:2578G
Jourdan PLC
24 October 2007


                                  Jourdan plc
                          ("Jourdan" or the "Company")

                                 AGM Statement


The Board of Jourdan announces that all of the resolutions considered at the
Annual General Meeting held earlier today were approved by shareholders.

Chairman, David Abell made the following statement to the meeting:

"Sales and profits for the first three months of this financial year were
outstanding, although by September order intake for those businesses affected by
the high street  -  Nelsons, Corby and in particular Suncrest - proved
disappointing.  Suncrest relies for a large part of its business on house
building and construction where order intake has been particularly poor.

Despite the downturn in the last few weeks, stock levels and costs continue to
be carefully managed at all three businesses with inventories within budget
levels and below last year.  An increasing percentage of components are sourced
from lower cost producers in China, although this too provides its own
challenges as a result of the lengthened supply chain.  Overall debt levels are
well below both budget and last year in spite of the cash purchase of Clinipak
and Prime Packaging Limited last year.

I am pleased to report that progress is being made with integrating Prime
Packaging into Nelsons.  A new management team is in place and we are able to
provide a much improved level of service to our enlarged customer base.  Our
medical packaging businesses, Westfield and Clinipak, continue to prosper with
sales and profits ahead of both budget and last year for the first quarter
although a much higher percentage than is usual of the order intake is for
delivery in the same month.  Both Prime Packaging and Clinipak have increased
the Group's product range and geographic spread.

As I indicated at the time of our full year results the outlook for the rest of
this financial year remains uncertain.  While the outlook for Westfield and
Clinipak is positive, we cannot express such optimism for Suncrest owing to its
dependence on retail, house building and construction.

We will continue to reduce the group's indebtedness during these more uncertain
economic times, although we shall also be seeking to take advantage of any
further complementary acquisition opportunities wherever these provide a
compelling opportunity to expand Jourdan's operating base."



Enquiries:

Jourdan plc                                              01476 403456
David Abell, Chairman

Charles Stanley Securities                               020 7149 6000
Nominated Adviser
Russell Cook / Carl Holmes


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
AGMILFIIIDLSFID

Jourdan (LSE:JDR)
Historical Stock Chart
From May 2024 to Jun 2024

Jourdan (LSE:JDR)
Historical Stock Chart
From Jun 2023 to Jun 2024